Florida Cancer Specialists & Research Institute | Strategic Alliance Partners

The platinum drugs, carboplatin and cisplatin, known for effectively treating lung, head and neck, breast, ovarian, gastric, bladder and testicular cancers, have been in short order for the past few months.

Finding a comprehensive cancer care provider that is able to provide patients with swift and easy access to the highest-quality diagnosis and treatment planning is essential to reducing stress and ensuring patients achieve the best possible outcomes.

Florida Cancer Specialists & Research Institute has introduced a new technology that provides multiple benefits for cancer patients receiving radiation therapy at the FCS Ocala Cancer Center.

Florida Cancer Specialists & Research Institute President & Managing Physician Lucio N. Gordan, MD, will join an expert panel of precision medicine leaders in Chicago this weekend to discuss the impact of genomic profiling.

Results of year-long collaborative effort between Florida Cancer Specialists & Research Institute and CVS Health/Aetna documented in newly released case study.

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Florida Cancer Specialists & Research Institute, LLC continues to forge new partnerships with alternative payment models and payers

A brief review of the POSEIDON trial, which analyzed durvalumab with or without tremelimumab in combination with chemotherapy in advanced NSCLC.

Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.

A comprehensive discussion on combination chemotherapy + immunotherapy regimens available to patients with advanced non–small cell lung cancer.

Shared insight on the value that molecular testing and PD-L1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Florida Cancer Specialists & Research Institute, LLC released a case study outlining the evolution of a newly FDA-approved first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Switching their focus to advanced non–small cell lung cancer, panelists identify parameters that may influence the use of immune checkpoint inhibitors in this setting.

Switching their focus to the adjuvant setting of resectable NSCLC, expert panelists identify treatment options in this setting and review the clinical data behind them.

Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.

Florida Cancer Specialists & Research Institute, LLC medical oncologist Richard McDonough, MD, is the recipient of the Florida Society of Clinical Oncology 2023 Dorothy Green Phillips Legacy Award.

Closing out their discussion on the management of cutaneous squamous cell carcinoma, expert panelists share clinical pearls and excitement for the future.

Expert oncologists reflect on key factors that aid in the selection of therapy for patients diagnosed with resectable non–small cell lung cancer (NSCLC).

Dr Vishal Patel shares a surgeon’s perspective on MDC, followed by a discussion on how intensifying treatment after surgery may improve outcomes for higher-risk patients with CSCC.

Experts in the field of CSCC revisit the concept of multidisciplinary care and consider best communication strategies.

Shared insight on novel treatment modalities in the setting of cutaneous squamous cell carcinoma and how they may be triaged moving forward.

Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.

A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.

Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.

Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute will join with colleagues this week to share the latest advances in oncology pharmacy operations and dispensing practices at the NCODA 2023 Spring Forum in Indianapolis.

Shared insight on the use of immune checkpoint inhibitors in other patient populations within the skin cancer paradigm, and how lessons may be applied to patients with CSCC.

Expert panelists consider the broader evolution of therapy in resectable stage II-IV cutaneous squamous cell carcinoma.

Expert perspectives on real-world, in-practice identification and management of patients with resectable CSCC.

Panelists round out their review of staging and risk stratification in CSCC by considering how each affects the selection of optimal surgical strategies.

Martin F. Dietrich, MD, PhD, discusses how mutational profiling can inform subsequent treatment selection for patients with non–small cell lung cancer.